The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease

Aging and Disease

Volumn 6, Issue 5, 2015, Pages 331-341

  Budni, Josiane ^a   Bellettini Santos, Tatiani ^a   Mina, Francielle ^a   Garcez, Michelle Lima ^a   Zugno, Alexandra Ioppi ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Aging; Alzheimer's disease; BNDF; GDNF; NGF

Indexed keywords

AMYLOID BETA PROTEIN; BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; OXIDOPAMINE; PIOGLITAZONE; SOMATOMEDIN B; TROPOMYOSINE RELATED KINASE RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

AGING; ALZHEIMER DISEASE; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; DEMENTIA; GENOTYPE; HUMAN; HYPOGLYCEMIA; ISCHEMIA; LONG TERM POTENTIATION; MEMORY DISORDER; NERVE CELL DIFFERENTIATION; NERVE CELL GROWTH; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SEIZURE; SIGNAL TRANSDUCTION;

EID: 84975764634     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2015.0825     Document Type: Review

References (110)

1. Guerin B, Hoorens S, Khodyakov D, Yaqub O (2015). A growing and ageing population.
2. Barrientos RM, Kitt MM, Watkins LR, Maier SF (2015). Neuroinflammation in the normal aging hippocampus: Neuroscience.
3. Morrison JH, Baxter MG (2012). The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci, 13(4):240-50.
4. Bishop NA, Lu T, Yankner BA (2010). Neural mechanisms of ageing and cognitive decline. Nature, 464(7288):529-35.
5. Baquer NZ, Taha A, Kumar P, McLean P, Cowsik SM, Kale RK, et al. (2009). A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology, 10(4):377-413.
6. Samanez-Larkin GR, Knutson B (2015). Decision making in the ageing brain: changes in affective and motivational circuits. Nat Rev Neurosci, 16(5):278-89.
7. Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky ST, et al. (2015). Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience, 12(15):00221-3.
8. Skaper SD (2012). The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol, 846:1-12.
9. Huang EJ, Reichardt LF (2001). Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci, 24:677-736.
10. Fuchikami M, Morinobu S, Kurata A, Yamamoto S, Yamawaki S (2009). Single immobilization stress differentially alters the expression profile of transcripts of the brain-derived neurotrophic factor (BDNF) gene and histone acetylation at its promoters in the rat hippocampus. Int J Neuropsychopharmacol, 12(1):73-82.
11. Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF (2015). Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: A meta-analysis. Psychiatry Res, 226(1):1-13.
12. Murer MG, Yan Q, Raisman-Vozari R (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol, 63(1):71-124.
13. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002). From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem, 9(5):224-37.
14. Islam O, Loo TX, Heese K (2009). Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res, 6(1):42-53.
15. Hibbert AP, Kramer BMR, Miller FD, Kaplan DR (2006). The localization, trafficking and retrograde transport of BDNF bound to p75NTR in sympathetic neurons. Mol Cell Neurosci, 32(4):387-402.
16. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci, 25(22):5455-63.
17. Silhol M, Arancibia S, Perrin D, Maurice T, Alliot J, Tapia-Arancibia L (2008). Effect of aging on brain-derived neurotrophic factor, proBDNF, and their receptors in the hippocampus of Lou/C rats. Rejuvenation Res, 11(6):1031-40.
18. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S (2008). New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev, 59(1):201-20.
19. Patterson SL (2015). Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1β, BDNF and synaptic plasticity. Neuropharmacology, 96(Pt A):11-8.
20. Cowansage KK, LeDoux JE, Monfils MH (2010). Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol, 3(1):12-29.
21. Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, Bennett L, et al. (1997). Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience, 78(2):431-48.
22. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S (2004). Physiology of BDNF: focus on hypothalamic function. Front Neuroendocrinol, 25(2):77-107.
23. Kennedy KM, Reese ED, Horn MM, Sizemore AN, Unni AK, Meerbrey ME, et al. (2015). BDNF val66met polymorphism affects aging of multiple types of memory. Brain Res, 1612:104-17.
24. Tong CW, Wang ZL, Li P, Zhu H, Chen CY, Hua TM (2015). Effects of senescence on the expression of BDNF and TrkB receptor in the lateral geniculate nucleus of cats. Dongwuxue Yanjiu, 36(1):48-53.
25. Komulainen P, Pedersen M, Hänninen T, Bruunsgaard H, Lakka TA, Kivipelto M, et al. (2008). BDNF is a novel marker of cognitive function in ageing women: The DR's EXTRA Study. Neurobiol Learn Mem, 90(4):596-603.
26. Petzold A, Psotta L, Brigadski T, Endres T, Lessmann V (2015). Chronic BDNF deficiency leads to an age-dependent impairment in spatial learning. Neurobiol Learn Mem, 120:52-60.
27. Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X, Nguyen P, et al. (2015). A gamma-Secretase Inhibitor, but Not a gamma-Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP. PLoS One, 10(2):e0118379.
28. Rage F, Silhol M, Binamé F, Arancibia S, Tapia-Arancibia L (2007). Effect of aging on the expression of BDNF and TrkB isoforms in rat pituitary. Neurobiol Aging, 28(7):1088-98.
29. Nakai S, Matsunaga W, Ishida Y, Isobe K-i, Shirokawa T (2006). Effects of BDNF infusion on the axon terminals of locus coeruleus neurons of aging rats. Neurosci Res, 54(3):213-9.
30. Matsunaga W, Shirokawa T, Isobe K (2004). BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain. Neurobiol Aging, 25(3):341-8.
31. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem, 93(6):1412-21.
32. Yasutake C, Kuroda K, Yanagawa T, Okamura T, Yoneda H (2006). Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci, 256(7):402-6.
33. Platenik J, Fisar Z, Buchal R, Jirak R, Kitzlerova E, Zverova M, et al. (2014). GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog Neuropsychopharmacol Biol Psychiatry, 50:83-93.
34. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. (2007). BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res, 41(5):387-94.
35. Forlenza OV, Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonca VA, et al. (2010). Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry, 11(6):774-80.
36. Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000). Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol, 57(6):846-51.
37. Gezen-Ak D, Dursun E, Hanagasi H, Bilgic B, Lohman E, Araz OS, et al. (2013). BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J Alzheimers Dis, 37(1):185-95.
38. Lee JG, Shin BS, You YS, Kim JE, Yoon SW, Jeon DW, et al. (2009). Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig, 6(4):299-305.
39. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, et al. (2010). Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res, 7(1):15-20.
40. Faria MC, Goncalves GS, Rocha NP, Moraes EN, Bicalho MA, Gualberto Cintra MT, et al. (2014). Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J Psychiatr Res, 53:166-72.
41. Forlenza OV, Teixeira AL, Miranda AS, Barbosa IG, Talib LL, Diniz BS, et al. (2015). Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. J Alzheimers Dis.
42. Ventriglia M, Zanardini R, Bonomini C, Zanetti O, Volpe D, Pasqualetti P, et al. (2013). Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int, 2013:901082.
43. Kao PF, Banigan MG, Vanderburg CR, McKee AC, Polgar PR, Seshadri S, et al. (2012). Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in early Alzheimer disease pathology. J Neuropathol Exp Neurol, 71(7):654-64.
44. Scott Bitner R (2012). Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem Pharmacol, 83(6):705-14.
45. Hu YS, Long N, Pigino G, Brady ST, Lazarov O (2013). Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3beta, neurotrophin-3 and CREB signaling. PLoS One, 8(5):e64460.
46. Chuu JY, Taylor JL, Tinklenberg J, Noda A, Yesavage J, Murphy GM, Jr. (2006). The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer's disease. J Alzheimers Dis, 9(1):43-9.
47. Akatsu H, Yamagata HD, Kawamata J, Kamino K, Takeda M, Yamamoto T, et al. (2006). Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord, 22(3):216-22.
48. Nagata T, Kobayashi N, Shinagawa S, Yamada H, Kondo K, Nakayama K (2014). Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. J Neural Transm, 121(4):433-41.
49. Sonali N, Tripathi M, Sagar R, Vivekanandhan S (2013). Val66Met polymorphism and BDNF levels in Alzheimer's disease patients in North Indian population. Int J Neurosci, 123(6):409-16.
50. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. (2013). BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging, 34(11):2457-64.
51. Hsiao YH, Hung HC, Chen SH, Gean PW (2014). Social interaction rescues memory deficit in an animal model of Alzheimer's disease by increasing BDNF-dependent hippocampal neurogenesis. J Neurosci, 34(49):16207-19.
52. Shin MK, Kim HG, Baek SH, Jung WR, Park DI, Park JS, et al. (2014). Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. Neurobiol Aging, 35(5):990-1001.
53. Han K, Jia N, Li J, Yang L, Min LQ (2013). Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. Mol Med Rep, 8(3):737-40.
54. Prakash A, Kumar A (2014). Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer's disease. Neurotox Res, 25(4):335-47.
55. Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. (2014). Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. Behav Brain Res, 268:88-93.
56. Chao MV, Hempstead BL (1995). p75 and Trk: a two-receptor system. Trends Neurosci, 18(7):321-6.
57. Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR, et al. (2001). The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor. J Biol Chem, 276(35):32687-95.
58. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. (2004). Sortilin is essential for proNGF-induced neuronal cell death. Nature, 427(6977):843-8.
59. Fahnestock M, Michalski B, Xu B, Coughlin MD (2001). The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci, 18(2):210-20.
60. Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, Longo FM, et al. (2002). ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron, 36(3):375-86.
61. Song W, Volosin M, Cragnolini AB, Hempstead BL, Friedman WJ (2010). ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J Neurosci, 30(46):15608-15.
62. Guo J, Wang J, Liang C, Yan J, Wang Y, Liu G, et al. (2013). proNGF inhibits proliferation and oligodendrogenesis of postnatal hippocampal neural stem/progenitor cells through p75NTR in vitro. Stem Cell Res, 11(2):874-87.
63. Wang YJ, Valadares D, Sun Y, Wang X, Zhong JH, Liu XH, et al. (2010). Effects of proNGF on neuronal viability, neurite growth and amyloid-beta metabolism. Neurotox Res, 17(3):257-67.
64. Al-Shawi R, Hafner A, Olsen J, Chun S, Raza S, Thrasivoulou C, et al. (2008). Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci, 27(8):2103-14.
65. Terry AV, Jr., Kutiyanawalla A, Pillai A (2011). Age-dependent alterations in nerve growth factor (NGF)-related proteins, sortilin, and learning and memory in rats. Physiol Behav, 102(2):149-57.
66. Korsching S, Auburger G, Heumann R, Scott J, Thoenen H (1985). Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. Embo J, 4(6):1389-93.
67. Larkfors L, Ebendal T, Whittemore SR, Persson H, Hoffer B, Olson L (1987). Decreased level of nerve growth factor (NGF) and its messenger RNA in the aged rat brain. Brain Res, 427(1):55-60.
68. Perovic M, Tesic V, Mladenovic Djordjevic A, Smiljanic K, Loncarevic-Vasiljkovic N, Ruzdijic S, et al. (2013). BDNF transcripts, proBDNF and proNGF, in the cortex and hippocampus throughout the life span of the rat. Age, 35(6):2057-70.
69. Hasenohrl RU, Soderstrom S, Mohammed AH, Ebendal T, Huston JP (1997). Reciprocal changes in expression of mRNA for nerve growth factor and its receptors TrkA and LNGFR in brain of aged rats in relation to maze learning deficits. Exp Brain Res, 114(2):205-13.
70. Yang C, Liu Y, Ni X, Li N, Zhang B, Fang X (2014). Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model. Neuropeptides, 48(4):233-8.
71. Parikh V, Howe WM, Welchko RM, Naughton SX, D'Amore DE, Han DH, et al. (2013). Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. Eur J Neurosci, 37(2):278-93.
72. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K (1993). NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun, 193(1):198-203.
73. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. (2006). Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord, 21(1):9-15.
74. Ji C, Song C, Zuo P (2011). The mechanism of memory impairment induced by Abeta chronic administration involves imbalance between cytokines and neurotrophins in the rat hippocampus. Curr Alzheimer Res, 8(4):410-20.
75. Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B, et al. (2015). Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis, 43(3):1059-72.
76. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, et al. (2012). Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol, 71(11):1018-29.
77. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A (2009). Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res, 6(2):158-70.
78. Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervos-Navarro J (1998). NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci, 16(7-8):787-94.
79. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. (1998). Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord, 9(5):246-57.
80. Mellott TJ, Pender SM, Burke RM, Langley EA, Blusztajn JK (2014). IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. PLoS One, 9(4):e94287.
81. Noh H, Seo H (2014). Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience, 266:255-65.
82. Ari C, Borysov SI, Wu J, Padmanabhan J, Potter H (2014). Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. Neurobiol Aging, 35(8):1839-49.
83. Peng S, Wuu J, Mufson EJ, Fahnestock M (2004). Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol, 63(6):641-9.
84. Podlesniy P, Kichev A, Pedraza C, Saurat J, Encinas M, Perez B, et al. (2006). Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol, 169(1):119-31.
85. Pedraza CE, Podlesniy P, Vidal N, Arevalo JC, Lee R, Hempstead B, et al. (2005). Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol, 166(2):533-43.
86. Deister C, Schmidt CE (2006). Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng, 3(2):172-9.
87. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 260(5111):1130-2.
88. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, et al. (1996). Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature, 381(6585):785-9.
89. Baloh RH, Tansey MG, Golden JP, Creedon DJ, Heuckeroth RO, Keck CL, et al. (1997). TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron, 18(5):793-802.
90. Jankovic J (2008). Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 79(4):368-76.
91. Pertusa M, Garcia-Matas S, Mammeri H, Adell A, Rodrigo T, Mallet J, et al. (2008). Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging, 29(9):1366-79.
92. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther, 138(2):155-75.
93. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med, 9(5):589-95.
94. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005). Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg, 102(2):216-22.
95. Farrand AQ, Gregory RA, Scofield MD, Helke KL, Boger HA (2015). Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice. Neurobiol Aging, 36(3):1569-76.
96. Matsunaga W, Isobe K, Shirokawa T (2006). Involvement of neurotrophic factors in aging of noradrenergic innervations in hippocampus and frontal cortex. Neurosci Res, 54(4):313-8.
97. Zurn AD, Winkel L, Menoud A, Djabali K, Aebischer P (1996). Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro. J Neurosci Res, 44(2):133-41.
98. Zurn AD, Baetge EE, Hammang JP, Tan SA, Aebischer P (1994). Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones. Neuroreport, 6(1):113-8.
99. Arenas E, Trupp M, Akerud P, Ibanez CF (1995). GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron, 15(6):1465-73.
100. Chao CC, Lee EH (1999). Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. Neuropharmacology, 38(6):913-6.
101. Cheng H, Fu YS, Guo JW (2004). Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus, 14(1):77-86.
102. Fox CM, Gash DM, Smoot MK, Cass WA (2001). Neuroprotective effects of GDNF against 6-OHDA in young and aged rats. Brain Res, 896(1-2):56-63.
103. McCullough MJ, Gyorkos AM, Spitsbergen JM (2013). Short-term exercise increases GDNF protein levels in the spinal cord of young and old rats. Neuroscience, 240(0):258-68.
104. Ghribi O, Herman MM, Forbes MS, DeWitt DA, Savory J (2001). GDNF protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. Neurobiol Dis, 8(5):764-73.
105. Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, et al. (2011). Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease. Curr Alzheimer Res, 8(8):853-9.
106. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, et al. (2011). Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging, 32(3):539-40.
107. Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR (2011). Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem, 286(52):45093-102.
108. Forlenza OV, Teixeira AL, Miranda AS, Barbosa IG, Talib LL, Diniz BS, et al. (2015). Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. J Alzheimers Dis, 3:3.
109. Revilla S, Sunol C, Garcia-Mesa Y, Gimenez-Llort L, Sanfeliu C, Cristofol R (2014). Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neuropharmacology, 81:55-63.
110. Revilla S, Ursulet S, Alvarez-Lopez MJ, Castro-Freire M, Perpina U, Garcia-Mesa Y, et al. (2014). Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther, 20(11):961-72.